


Q1 Please enter your company specific code as provided by Julian Arbuckle. Please note that each company will submit responses for this general questionnaire only once. Code number

Answered: 15 Skipped: 0


Q2 What type of company are you representing?

Answered: 15 Skipped: 0



Answer Choices	Responses	
Small biotech (<1000 employees)	6.67%	1
Mid to large size biotechnology (>1000 - <=10,000 employees)	26.67%	4
Big pharma (>10,000 employees)	66.67%	10
Total		15


Q3 Is your company currently using (internally or externally sourced) Next Generation Sequencing (NGS) technologies for clinical PGx studies?



Answer Choices	Responses	
Yes	80.00%	12
No	20.00%	3
Total		15

Q4 How often does your company currently use NGS technologies for clinical PGx studies?


Answered: 15 Skipped: 0



Answer Choices	Responses	
Widely used	46.67%	7
Occasionally used	33.33%	5
Rarely used	6.67%	1
Never used	13.33%	2
Total		15


Q5 Is your company planning to use (internally or externally sourced) NGS technologies in the next 12 months for clinical PGx studies?

Answered: 15 Skipped: 0




Answer Choices	Responses	
Yes	80.00%	12
No	6.67%	1
Considering to use	13.33%	2
Total		15

Q6 Do you see the application of NGS technologies for clinical PGx studies at your company in the next 5 years to be:




Answer Choices	Responses	
Widely used	66.67%	10
Occasionally used	26.67%	4
Rarely used	0.00%	0
Never used	6.67%	1
Total		15

Q7 For current clinical NGS studies what types of studies are being conducted (check all that apply):




Answer Choices	Responses
RNAseq	92.86% 13
DNA germline sequencing	78.57% 11
DNA somatic sequencing	78.57% 11
Viral sequencing (DNA/RNA)	21.43% 3
Microbiome sequencing	28.57% 4
Total Respondents: 14	

Q8 For DNA sequencing which approaches are being utilized (check all that apply):




Answer Choices	Responses	
Whole-genome	57.14%	8
Whole-exome	71.43%	10
Targeted panels	92.86%	13
Total Respondents: 14		

Q9 Which indications are using NGS for clinical PGx studies at your company (check all that apply):



Answer Choices	Responses
Cardiovascular	14.29% 2
Metabolism	14.29% 2
Neurosciences	64.29% 9
Immunology	71.43% 10
Infectious diseases	28.57% 4
Rare diseases	42.86% 6
Oncology	85.71% 12
Total Respondents: 14	


Q10 Which phases of clinical development have utilized NGS technologies at your company? (check all that apply)



Answer Choices	Responses	Count
Preclinical or research focused	78.57%	11
Phase I	78.57%	11
Phase IIa	92.86%	13
Phase IIb	85.71%	12
Phase III	78.57%	11
Phase IV	21.43%	3
Total Respondents: 14		

Q11 For preclinical NGS efforts, are the studies being conducted by:


Answered: 13 Skipped: 2



Answer Choices	Responses
In-house in discovery teams	7.69% 1
In collaboration with external collaborators (academic centers/medical institutions and/or other companies)	23.08% 3
Both in-house and with external collaborators	69.23% 9
Total	13

Q12 Is your company's clinical PGx NGS lab work being performed in-house or by external vendors/partners?


Answered: 13 Skipped: 2



Answer Choices	Responses
In-house only	0.00% 0
Outside external vendors or partners only	46.15% 6
Both	53.85% 7
Total	13


Q13 Is your company's clinical PGx NGS analysis being performed in-house or by external vendors/ partners?

Answered: 13 Skipped: 2



Answer Choices	Responses	
In-house only	23.08%	3
Outside external vendors or partners only	7.69%	1
Both	69.23%	9
Total		13


Q14 For Oncology studies is NGS being performed on (check all that apply):



Answer Choices	Responses	Count
Tumor-matched normal tissue or germline	61.54%	8
Primary tumors	69.23%	9
Metastatic tumors	53.85%	7
Fresh Frozen	76.92%	10
FFPE	92.31%	12
CTCs	30.77%	4
Circulating tumor DNA	69.23%	9
Immune-related cells or tissues	38.46%	5
No PGx oncology NGS studies have been performed	7.69%	1
Total Respondents: 13		


Q15 Do you see the application of NGS technologies for clinical PGx studies at your company as a clinical assay (i.e. CLIA validated) in the next 5 years?

Answered: 14 Skipped: 1



Answer Choices	Responses	
Yes	85.71%	12
No	14.29%	2
Total		14

Q16 Does your company have a policy for returning NGS generated results to patients participating in exploratory PGx studies in clinical trials? (Check all that apply)



Answer Choices	Responses
Will not return results under any circumstances	30.00% 3
Only returned if NGS or follow-up assays performed under CLIA regulations	40.00% 4
Only returned in countries where it is required by law	60.00% 6
Only returned for incidental findings	0.00% 0
In some circumstances exploratory results can be returned	20.00% 2
Total Respondents: 10	